Trulieve Cannabis (TRLV) vs. The Competition Head-To-Head Analysis

Trulieve Cannabis (NYSE:TRLV) is one of 897 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Trulieve Cannabis to related businesses based on the strength of its valuation, profitability, dividends, institutional ownership, risk, earnings and analyst recommendations.

Insider & Institutional Ownership

32.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for Trulieve Cannabis and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1	1	1	0	2.00
Trulieve Cannabis Competitors	7765	13847	25696	1031	2.41

Trulieve Cannabis presently has a consensus price target of $15.00, suggesting a potential upside of 46.34%. As a group, “Pharmaceuticals” companies have a potential upside of 23.98%. Given Trulieve Cannabis’ higher possible upside, research analysts clearly believe Trulieve Cannabis is more favorable than its peers.

Profitability

This table compares Trulieve Cannabis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	-41.55%	-4.24%	-1.72%
Trulieve Cannabis Competitors	-2,380.91%	-221.72%	-15.99%

Earnings and Valuation

This table compares Trulieve Cannabis and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Trulieve Cannabis	$1.18 billion	-$116.38 million	93.18
Trulieve Cannabis Competitors	$3.54 billion	$3.17 billion	546.63

Trulieve Cannabis’ peers have higher revenue and earnings than Trulieve Cannabis. Trulieve Cannabis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Trulieve Cannabis peers beat Trulieve Cannabis on 8 of the 12 factors compared.

About Trulieve Cannabis

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.